Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article provides an introduction to gender-affirming hormone therapy for transgender and gender-nonbinary patients, designed as a continuing education activity, but does not report new clinical results.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

This review discusses the relevance of human androgen receptor action in sports doping and examines the potential of cell-based biological assays for detecting androgenic anabolic steroid use, without presenting new research findings.

This study outlines a hair regrowth treatment targeting hair follicle stem cells, 5-alpha reductase pathway, and microinflammation using PDGF and VEGF, but reports no clinical results.

This study showed that androgenetic alopecia independently predicted higher mortality from diabetes and heart disease in both men and women, with increased rates in individuals with moderate or severe AGA.

This article reviews approved treatments for androgenetic alopecia and reports no new research findings, highlighting the need for further studies.

This abstract reports no new research findings and instead provides information about the JAMA website features and usage terms.

In this study, a taurine-based ionic liquid was developed to effectively penetrate the skin barrier and deliver antioxidants to hair follicles, reducing oxidative stress and promoting hair regrowth in an androgenic alopecia animal model.

In this study, researchers found that methanol extract from E. alba stem reduced the expression of the apoptosis marker gene Caspase-3 in T47D breast cancer cells, particularly at 100 ppm, achieving 1.859 times suppression compared to DMSO 2%.

This review discusses the pathogenesis and treatment of androgenetic alopecia, highlighting genome associations and newer topical formulations, but reports no new clinical results.

Androgenetic alopecia is the main reason people lose hair, and while some think it's normal, others find it abnormal and want treatment.

This review discusses cardiovascular risks associated with androgen deprivation therapy in prostate cancer patients and highlights ongoing research, including the potential reduced COVID-19 susceptibility, but reports no new results.

This study identified altered neurological pathways and potential drug targets involved in androgenetic alopecia, suggesting areas for future research and possible therapies.

This study suggests that the residues Val-889 and Arg-752 in the androgen receptor steroid binding domain are crucial for the intermolecular interaction necessary for receptor dimerization and function.

Gynostemma pentaphyllum extract may help grow hair and prevent graying.

Botulinum toxin may help treat male pattern baldness.

In this study, a new formulation of all-trans retinoic acid bound to polyvinyl alcohol showed reduced skin inflammation and sustained drug release for up to six days compared to free ATRA in vitro and in vivo.

This study found that in androgenetic alopecia patients, there is enhanced expression of type 2 TGF-β and type II receptors in hair follicles, suggesting a link to hair growth cycle changes.

This study suggests 5α‐androstan‐3α‐17β‐diol may be the true inducer of kidney enzymes in certain mice, while its induction mechanism likely involves pinocytosis rather than a receptor protein.

This study found that Gsdma3 mutation in mice allows hair follicles to bypass a typical telogen phase and directly enter the anagen phase, suggesting Gsdma3's role in hair cycle transitions by regulating Wnt signaling.

This study found that neither caffeine nor N,N-dimethylglycine treatments were toxic to balding or nonbalding dermal papilla cells and could stimulate calcium influx, indicating treatment responsiveness.

This study found that overexpression of the lncRNA AL136131.3 may inhibit hair shaft growth and promote hair follicle apoptosis in androgenetic alopecia by influencing key metabolic pathways.

This study found that the retinoid all-trans retinoic acid induced a catagen-like stage in human scalp hair follicles, suggesting upregulation of TGF-beta2 as a contributing mechanism.

This study reports that Abelson Interactor 1 (ABI1) regulates androgen receptor transcription in prostate cancer, identifying it as a potential target for new therapies addressing treatment resistance.

In this study, algal oligosaccharides effectively countered key factors in androgenetic alopecia pathogenesis, improving hair growth indicators in vitro and in mice.

This study reported that an ATRA-loaded nanostructured lipid carrier gel (ATRA-NLC-Gel) improved symptoms of alopecia areata in mice by enhancing transdermal drug delivery, reducing skin irritation, and promoting hair regrowth through targeted follicle enrichment and pathway activation.

This study suggests that TGase 3 may contribute to hair fiber scaffolding by forming specific isopeptide bonds between keratin intermediate filaments and keratin-associated proteins.

This study found that Regenera ActivaAMT significantly improved hair growth and patient satisfaction in both men and women with Androgenetic Alopecia, suggesting it may be an effective alternative to hair transplants.

In this study, PGD2 treatment in keratinocytes increased testosterone production via reactive oxygen species, suggesting a potential role for the NRF2 pathway in androgenic alopecia treatment strategies.

This literature review found that androgenetic alopecia has a complex multifactorial etiology and effective management should be tailored to individual severity and gender to improve patients' quality of life.